Newsletter October 2016
Sound Choice continues its quest to inform the public on vaccine studies. Our upcoming publication is a detailed summary of the talk presented by our Medical Scientist, Dr. Peter Jarzyna, during the American Association of Pro-Life Obstetricians and Gynecologists Conference in Houston in Feb 2016.
The title of the paper is “Insertional Mutagenesis and Autoimmunity Induced Disease Caused by Human Fetal and Retrovial Residual Toxins in Vaccines.” Below is the summary of the paper.
UNDERSTAND VACCINE MANUFACTURING AND CONTAMINANT LEVELS
Regulatory agencies initally argued in early guidance meetings for a recommended limit of 10 pg contamining cell-substrate DNA per vaccine dose, which was later on loosened to 100 pg in 1986 (WHO Study Group; Geneva). Following an additional change based on a World Heath Organization (WHO) meeting in 1997, the currently recommended maximal amount of residual cell-substrate DNA per dose in a vaccine produced in a continuous cell line is 10 ng, a thousand times more than the inital value. None of the thresholds was based upon data or empirical study to justify the guidance. The WHO itself names two risks on their website concerning the “Safety of residual cellular DNA in vaccines”:
- transmission of latent viruses and other agents
- incorporation of cellular DNA into host genetic materials
The current WHO guidance of less than 10 ng cell substrate DNA per vaccine dose is well exceeded by contaminating DNA levels in the rubella, mumps-measels-rubella (MMR), chickenpox and some hepatitis A vaccines available in the US.The chickenpox vaccine available in the US is contaminated with greater than 2 mg fetal MRC-5 DNA, according to the manufacturer’s measurements. This is 200 times more than what the WHO recommends in their guidelines.
A SCIENTIFIC EXPLANATION
The unwanted DNA of the rubella vaccine is fragmented during the manufacturing process into short pieces of approximately 215 base pairs (in average) in length, which is ideal for cellular uptake and genomic integration. Recommendations to fragment the contaminating DNA arose from the concern that an entire cancer causing gene might be present among the fetal DNA contaminants. However, it has been scientifically shown that contrary to the integration of large DNA gene lengths, integration of short DNA fragments has been demonstrated to be much more efficient.
Furthermore, two vaccines (hepatitis A and rubella) are also contaminated with fragments of the Human Endogenous Retrovirus K (HERVK), a retrovirus that invades the genome of its host, can be re-activatable and which can facilitate the integration of foreign DNA into the host’s genome. HERVK is in the same family of retroviruses as the MMLV virus used in the gene therapy trial, in which inappropriate gene insertion led to subsequent additional somatic mutations and cancer in 4 of 9 young boys. Short DNA fragments are known to integrate into the genome in a species specific manner and can lead to an autoimmune response as well as mutagenesis and/or genomic instability.
AN UNSTUDIED RISK TO VACCINE RECIPIENTS
As covered in detail in our last newsletter, the vaccine schedule exposes young children to insertion of fetal DNA fragments during a time of significant brain development. Despite the overwhelming body of scientific literature clearly demonstrating the high probability of autoimmune and/or insertional mutagenesis dangers from these contaminants, retroviral fragments as well as residual human diploid DNA are an unstudied risk to vaccine recipients. This is an unacceptable danger that undoubtedly cries out for serious epidemiological and scientific investigation.
is to disclose fetal DNA quantities in vaccine package inserts. Moreover, we emphasize the fact that alternatives are already available and manufactured in other countries. A rubella vaccine available in Japan clearly demonstrates that vaccines can be safely and effectively manufactured in animal based cell lines, eliminating the dangers of residual human DNA and retroviral contaminants. This Japanese vaccine is based on Takahashi strains of live attenuated rubella virus and is produced on rabbit kidney cells . It has been recently proven that while Japan implemented the single-dose rubella vaccination program until 2006, a single dose of this vaccine was capable to retain immunity for at least 10 years when rubella was under regional control. SCPI is currently conducting a study to provide further clinical proof for autoimmunity caused by fetal DNA found in vaccines.